Comparison of different classes of drugs for Management of Acute Coronary Syndrome (ACS): A brief communication

• 발행기관: 셀메드 세포교정의약학회
• 저자명: Jonaid Ahmad Malik Mudasir Maqbool Tawseef Ahmad Hajam Muhammad Abrar Khan Mehrukh Zehravi
• 간행물 정보: 『셀메드』Volume 11 Issue 2, 1~5쪽, 전체 5쪽
• 주제분류: 의약학 > 의학일반
• 파일형태: PDF
• 발행일자: 2021.05.30

영문 초록

Acute coronary syndrome (ACS) is a class of conditions consisting of NSTEMI (non-ST-elevated myocardial infarction), STEMI (ST-elevated myocardial infarction), unstable angina, ranging from myocardial ischaemic states, as well as there is usually a mismatch with respect to both blood supply and blood demand marked by chest pain. Indian patients with ACS have a higher STEMI score than patients of established countries'. Since most of these patients were poor, they were less likely to receive adequate therapy and had a higher death rate of 30 days. In India, ACS patients appear to be young from low socioeconomic backgrounds and have higher ST-elevated MI rates than do patients of established countries'. In India, patients get late medical treatment and inadequate access to proven therapies. Hypertension, hyperlipidemia, diabetes, obesity, cigarette use and a family history of atherosclerotic disease are important risk factors attributed to ACS. Most of the general therapy for ACS focuses on reducing myocardial ischemia and pain suppression. Because of the time dependence of the condition, the onset of signs and arrival at the hospital for the treatment of ACS is very important. This time gap between the onset of symptoms and hospital appearance is larger in India relative to western countries. This paper will concentrate on ACS management and a brief on comparative study of various groups of drugs available with regard to clinical trials and guidelines, respectively.

키워드

Management Acute coronary syndrome therapies Angina